Seroepidemiology of enterovirus D68 in a healthy population in Beijing, China, between 2012 and 2017: A retrospective study.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
06 2021
Historique:
revised: 19 05 2020
received: 23 01 2020
accepted: 21 05 2020
pubmed: 4 6 2020
medline: 9 10 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

To investigate the seroepidemiological features of enterovirus D68 (EV-D68) in the healthy population from 2012 to 2017 in Beijing, China. A retrospective cross-sectional investigation was conducted using serum specimens collected from healthy individuals in Beijing from 2012 to 2017. These samples were tested for neutralization antibodies (NtAbs) against EV-D68. The sera from six EV-D68 infected patients in the acute or convalescent phase were used to determine the protection level of NtAbs against EV-D68. The geometric means of the titers (GMT) of EV-D68 NtAbs in 2012 and 2017 were 92.82 and 242.91, respectively; the seroprevalences of EV-D68 were 89.43% and 98.43%, respectively. The GMT reached its peak in the 11 to 15 age group in 2012, while in 16 to 20 age group in 2017. We also observed that EV-D68 NtAbs titers of six sera from the acute phase were all less than equal to  1:64 and that of three sera from the convalescent phase were all more than 1:64. Anti-EV-D68 NtAbs in the population remained low from 2012 to 2016 but increased significantly in 2017. Although most of the EV-D68 infections remain undetected in Beijing, the risk of a large outbreak of EV-D68 exists and should be taken seriously.

Identifiants

pubmed: 32492201
doi: 10.1002/jmv.26132
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3524-3531

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis. 2016;16:e64-e75.
Wang G, Zhuge J, Huang W, et al. Enterovirus D68 subclade B3 strain circulating and causing an outbreak in the United States in 2016. Sci Rep. 2017;7:1242.
Knoester M, Schölvinck EH, Poelman R, et al. Upsurge of enterovirus D68, the Netherlands, 2016. Emerg Infect Dis. 2017;23:140-3.
Dyrdak R, Grabbe M, Hammas B, et al. Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016. Euro Surveill. 2016;21:30403.
Imamura T, Suzuki A, Meijer A, et al. Clusters of acute respiratory illness associated with human enterovirus 68 -- Asia, Europe, and United States, 2008-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1301-1314.
Imamura T, Fuji N, Suzuki A, et al. Enterovirus 68 among children with severe acute respiratory infection, the Philippines. Emerg Infect Dis. 2011;17:1430-1435.
Lang M, Mirand A, Savy N, et al. Acute flaccid paralysis following enterovirus D68 associated pneumonia, France, 2014. Euro Surveill. 2014;19:20952.
Yoder JA, Lloyd M, Zabrocki L, Auten J. Pediatric acute flaccid paralysis: enterovirus D68-associated anterior myelitis. J Emerg Med. 2017;53:e19-e23.
Dyda A, Stelzer-Braid S, Adam D, Chughtai AA, MacIntyre CR. The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation. Euro Surveill. 2018;23(3):17-00310.
Messacar K, Schreiner TL, Maloney JA, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385:1662-1671.
Meijer A, van der Sanden S, Snijders BE, et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology. 2012;423:49-57.
Reiche J, Böttcher S, Diedrich S, et al. Low-level circulation of enterovirus D68-associated acute respiratory infections, Germany, 2014. Emerg Infect Dis. 2015;21:837-841.
Smura T, Ylipaasto P, Klemola P, et al. Cellular tropism of human enterovirus D species serotypes EV-94, EV-70, and EV-68 in vitro: implications for pathogenesis. J Med Virol. 2010;82:1940-1949.
Xiang Z, Li L, Ren L, et al. Seroepidemiology of enterovirus D68 infection in China. Emerg Microbes Infect. 2017;6:e32.
Sun S, Gao F, Hu Y, et al. A cross-sectional seroepidemiology study of EV-D68 in China. Emerg Microbes Infect. 2018;7:99.
Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvarangan R. Neutralizing antibody against enterovirus D68 in children and adults before 2014 outbreak, Kansas City, Missouri, USA1. Emerg Infect Dis. 2019;25:585-588.
Zhang Y, Moore DD, Nix WA, Oberste MS, Weldon WC. Neutralization of enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. J Clin Virol. 2015;69:172-175.
Xiang Z, Gonzalez R, Wang Z, et al. Coxsackievirus A21, enterovirus 68, and acute respiratory tract infection, China. Emerg Infect Dis. 2012;18:821-824.
Shen L, Gong C, Xiang Z, et al. Upsurge of enterovirus D68 and circulation of the new subclade D3 and subclade B3 in Beijing, China, 2016. Sci Rep. 2019;9:6073.
Zhang T, Ren L, Luo M, et al. Enterovirus D68-associated severe pneumonia, China, 2014. Emerg Infect Dis. 2015;21:916-8.
World Health Organization (WHO). Guidelines for WHO/EPI collaborative studies on poliomyelitis. Standard Procedure for Determining Immunity to Poliovirus Using the Microneutralization Test. Geneva, Switzerland: World Health Organization; 1993. http://www.who.int/iris/handle/10665/70486
Midgley CM, Jackson MA, Selvarangan R, et al. Severe respiratory illness associated with enterovirus D68 - Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep. 2014;63:798-799.
Liu Y, Sheng J, Fokine A, et al. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science. 2015;347:71-74.

Auteurs

Yang Liu (Y)

College of Public Health, Capital Medical University, Beijing, China.

Cheng Gong (C)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Ming Luo (M)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Tiegang Zhang (T)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Maozhong Li (M)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Lingyu Shen (L)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Herun Zhang (H)

Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Fang Huang (F)

College of Public Health, Capital Medical University, Beijing, China.
Planned Immunity Inoculation Institute, Beijing Center for Disease Prevention and Control, Beijing, China.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH